{
  "claim_id": "claim_000",
  "claim": "Flublok ensures identical antigenic match with WHO- and FDA-selected flu strains.",
  "document": "Hsiao_et_al.__2023_",
  "verification_stats": {
    "total_extracted": 2,
    "verified": 0,
    "rejected": 2,
    "verification_rate": 0.0
  },
  "verified_evidence": [],
  "rejected_evidence": [
    {
      "id": 1,
      "quote": "BACKGROUND Quadrivalent recombinant influenza vaccines contain three times the amount of hemagglutinin protein as standard dose egg based vaccines, and the recombinant formulation is not susceptible to antigenic drift during manufacturing.",
      "reason": "does not support claim",
      "original_explanation": "This quote directly states that the recombinant vaccine (Flublok) is not susceptible to antigenic drift during manufacturing, which supports the claim that it ensures an identical antigenic match with WHO- and FDA-selected flu strains."
    },
    {
      "id": 2,
      "quote": "The effectiveness of standard dose vaccines - especially against the influenza A H3N2 subtype - may be attenuated by antigenic drift during egg based manufacturing, whereas the recombinant vaccine is not susceptible to such drift.",
      "reason": "does not support claim",
      "original_explanation": "This quote contrasts standard dose (egg-based) vaccines, which can experience antigenic drift, with the recombinant vaccine, which is not susceptible to this issue, supporting the claim that Flublok maintains an identical antigenic match to the selected strains."
    }
  ],
  "model_used": "gpt-4.1"
}